Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
An analyst at a prominent research firm initiated coverage of the
Overview
An analyst's rather bullish initiation of coverage shone a light on Lexicon Pharmaceuticals (NASDAQ: LXRX) stock on Monday. Investors clearly took notice of this, as they piled into the company's stock to send it to a gain of nearly 6% on the day.
Before market open, Cantor Fitzgerald prognosticator Steve Seedhouse flagged Lexicon as an overweight (buy, in other words) at a price target of $8 per share. That's more than four times the stock's current level of $1.90.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.